series-a
Stage
1
Investors
About
IMIDomics develops first-in-class medicines and biomarkers for immune-mediated inflammatory diseases (IMIDs) using a proprietary patient-centric data platform that integrates clinical and biomolecular data from over 17,000 patients.
Explore IMIDomics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.